Isaac Garcia-Murillas

Isaac Garcia-Murillas has been instrumental in developing personalized ctDNA tracking assays for monitoring treatment response and detecting minimal residual disease in breast cancer, demonstrating that ctDNA detection after neoadjuvant chemotherapy predicts relapse with high specificity months before clinical recurrence. His research at the Institute of Cancer Research has established the clinical utility of serial ctDNA monitoring for real-time assessment of therapy effectiveness in early-stage breast cancer. His work has been foundational in establishing ctDNA as a tool for treatment adaptation and early intervention in breast cancer management.